SamerNakhleMD

Endocrinology • Las Vegas, NV

Diabetes, Lipid Metabolism

Endocrinologist at Palm medical group

Join to view full profile

Dr. Nakhle is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nakhle's full profile

Already have an account?

Office
9280 W Sunset Rd
Ste 306
Las Vegas, NV 89148
Phone+1 702-696-7256

Fax+1 702-796-7256

Education & Training

University of Nebraska Medical Center College of MedicineFellowship, Endocrinology, Diabetes, and Metabolism, 1998 - 2000
St Barnabas HospitalResidency, Internal Medicine, 1995 - 1998
Damascus University Faculty of MedicineClass of 1991

Certifications & Licensure

NV State Medical License 2001 - 2025
IA State Medical License 2000 - 2002
IN State Medical License 2000 - 2001

Awards, Honors, & Recognition

Fellow (FACE) American Association of Clinical Endocrinology

Clinical Trials

An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Approved for marketing
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) Start of enrollment: 2014 Feb 01
Terminated
Phase 4
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2014 Apr 01
Terminated
Phase 2
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol Start of enrollment: 2014 Oct 01
Terminated
Phase 3
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM Start of enrollment: 2015 Sep 01
Completed
Phase 2
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2015 Oct 20
Completed
Phase 3
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2017 May 24
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Dia...
Elena A Christofides, Andrzej Stankiewicz, Douglas Denham, Diego Bellido, Edward Franek
Endocrine Practice. 2024-09-01
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 di...
Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari
Diabetes, Obesity & Metabolism. 2024-06-01
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: ...
Viral N Shah, Amer Al-Karadsheh, Cathy Barnes, Jose Mandry, Samer Nakhle
Journal of Diabetes Science and Technology. 2024-02-29

Lectures

PTH/PTHrP and CaSR Signaling
ENDO 2019 - New Orleans, LA - 3/26/2019

Press Mentions

Health Care Quarterly’s 2020 Top DoctorsAugust 20th, 2020

Professional Memberships

Endocrine Society - ENDO
Member

Other Languages

Arabic